Skip to main content

Advertisement

SpringerLink
Log in

Update in the management of ovarian and cervical carcinoma

  • Special Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Ovarian and cervical cancers are significant health problems. This article provides an update in selected management topics. Paclitaxel and platinum derivatives are the first-line treatment for patients with advanced disease. In selected patients, intraperitoneal chemotherapy has been associated with improved survival but the broad applicability of this strategy is limited by issues of toxicity and feasibility. Management of patients with recurrent disease is based on a number of factors and includes surgery in selected cases, platinum-based chemotherapy for patients with platinum-sensitive disease and other agents such as topotecan and pegylated liposomal formulation of doxorubicin for patients with platinum-resistant disease. In cervical cancer, the most significant issue/event is the demonstration of superior survival with topotecan and cisplatin compared to cisplatin alone. Finally, new agents such as epidermal growth factor receptor inhibitors and antiangiogenic agents are being currently tested in these settings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sugarbaker PH, Mora JT, Carmignani P et al (2005) Update on chemotherapeutic agents utilized for perioperative intraperitoneal CT. Oncologist 10:112–122

    Article  PubMed  CAS  Google Scholar 

  2. Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 14:277–283

    Article  CAS  Google Scholar 

  3. Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955

    Article  PubMed  CAS  Google Scholar 

  4. Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19:1001–1007

    PubMed  CAS  Google Scholar 

  5. Armstrong DK, Bundy B, Wenzel L et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  PubMed  CAS  Google Scholar 

  6. Jaaback K, Johnson N (2006) Intraperitoneal CT for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 1:CD005340

  7. Gore M, du Bois A, Vergote I (2006) Intraperitoneal CT in ovarian cancer remains experimental. J Clin Oncol 24:4528–4530

    Article  PubMed  Google Scholar 

  8. Pecorelli S (2006) The standard of therapy for advanced ovarian cancer: a global perspective. Educational Session, ASCO annual meeting

  9. Thigpen JT, Brady MF, Omura GA et al (1993) Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 71:606–614

    Article  PubMed  CAS  Google Scholar 

  10. Eisenhauer EA, Vermorken JB, Van Glabbeke M (1997) Predictors of response to subsequent CT in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8:963–968

    Article  PubMed  CAS  Google Scholar 

  11. Markman M, Reichman B, Hakes T et al (1991) Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9:1801–1805

    PubMed  CAS  Google Scholar 

  12. Markman M, Markman J, Webster K et al (2004) Duration of response to second-line, platinum-based CT for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 22:3120–3125

    Article  PubMed  CAS  Google Scholar 

  13. Gore ME, Fryatt I, Wiltshaw E, Dawson T (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207–211

    Article  PubMed  CAS  Google Scholar 

  14. Spriggs D (2003) Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 90:S39–S44

    Article  PubMed  CAS  Google Scholar 

  15. Armstrong DK (2002) Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist. 7:20–28

    Article  PubMed  CAS  Google Scholar 

  16. Kavanagh J, Tresukosol D, Edwards C et al (1995) Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13:1584–1588

    PubMed  CAS  Google Scholar 

  17. Spriggs DR (2002) Platinum treatment of presumed platinum resistant ovarian cancer after nonplatinum therapy [abstract]. Proc Am Soc Clin Oncol 21:A877

    Google Scholar 

  18. Ten Bokkel Huinink W, Gore M, Carmichael J et al (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183–2193

    PubMed  CAS  Google Scholar 

  19. Creemers GJ, Bolis G, Gore M et al (1996) Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14:3056–3061

    PubMed  CAS  Google Scholar 

  20. Bookman MA, Malmstrom H, Bolis G et al (1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior CT that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345–3352

    PubMed  CAS  Google Scholar 

  21. McGuire WP, Blessing JA, Bookman MA et al (2000) Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 18:1062–1067

    PubMed  CAS  Google Scholar 

  22. Horowitz NS, Hua J, Giba R K et al (2004) The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol Oncol 94:67–73

    Article  PubMed  CAS  Google Scholar 

  23. Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based CT versus conventional platinum-based CT in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099–2106

    Article  PubMed  CAS  Google Scholar 

  24. González-Martin AJ, Calvo E, Bover I et al (2005) Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Españole de Investigación en Cancer de Ovario) study. Ann Oncol 16:749–755

    Article  PubMed  Google Scholar 

  25. Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699–4707

    Article  PubMed  CAS  Google Scholar 

  26. Markman M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393

    PubMed  CAS  Google Scholar 

  27. Markman M, Hoskins W (1992) Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definition of the treated population. J Clin Oncol 10:513–514

    PubMed  CAS  Google Scholar 

  28. Thigpen JT, Vance RB, Khansur T (1993) Second-line CT for recurrent carcinoma of the ovary. Cancer 71:1559–1564

    PubMed  CAS  Google Scholar 

  29. (2005) Guidelines by the National Institute of Clinical Excellence (NICE). Available on WWW at http://www.nice.org.uk

  30. Chi DS, McCaughty K, Diaz JP (2006) Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106:1933–1939

    Article  PubMed  Google Scholar 

  31. Harter P, du Bois A, Hahmann M (2006) Surgery in recurrent ovarian cancer: the Arbeitsgeminschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–1710

    Article  PubMed  Google Scholar 

  32. Doyle C, Crump M, Pintilie M, Oza AM (2001) Does palliative CT palliate? Evaluation of expectations, outcomes, and costs in women receiving CT for advanced ovarian cancer. J Clin Oncol 19:1266–1274

    PubMed  CAS  Google Scholar 

  33. Eisenhauer EA, Vermorken JB, Van Glabbeke M (1997) Predictors of response to subsequent CT in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8:963–968

    Article  PubMed  CAS  Google Scholar 

  34. Leitao MM, Hummer A, Dizon DS et al (2003) Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol 91:123–129

    Article  PubMed  CAS  Google Scholar 

  35. Ten Bokkel, Huinink W, Lase SR, Ross GA (2004) Long-term survival in a phase III, randomized study of topotecan versus paclitaxel in advanced epithelial ovarian cancer. Ann Oncol 15:100–103

    Article  Google Scholar 

  36. Gordon AN, Fleagle JT, Guthrie D et al (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubic in versus topotecan. J Clin Oncol 19:3312–3322

    PubMed  CAS  Google Scholar 

  37. Bookman MA (2005) Is there still a role for hormonal therapy? Int J Gynecol Cancer 15:291–297

    Article  PubMed  Google Scholar 

  38. Howley PM (2001) In: Fields BN, Knipe DM, Howley PM (eds) Fields virology, 4th Edn. Lippincott-Raven, Philadelphia, PA, pp 2197–2229

    Google Scholar 

  39. Rose PG, Bundy BN, Watkins EB (1999) Concurrent cisplatin-based radiotherapy and CT for locally advanced cervical cancer. N Engl J Med 340:1144–1153

    Article  PubMed  CAS  Google Scholar 

  40. Bonomi P, Blessing JA, Stehman FB et al (1985) Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3:1079–1085

    PubMed  CAS  Google Scholar 

  41. Omura GA, Blessing JA, Vaccarello L et al (1997) Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15:165–171

    PubMed  CAS  Google Scholar 

  42. Bloss JD, Blessing JA, Behrens BC et al (2002) Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 20:1832–1837

    Article  PubMed  CAS  Google Scholar 

  43. Rose PG, Blessing JA, Gerhenson D, McGehee R (1999) Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 17:2676–2680

    PubMed  CAS  Google Scholar 

  44. Moore DH, Blessing JA, McQuellon RP et al (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22:3113–3119

    Article  PubMed  CAS  Google Scholar 

  45. Long H, Bundy BN, Grendys EC et al (2005) Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23:4626–4633

    Article  PubMed  CAS  Google Scholar 

  46. Ciardiello F, Tortora G (2002) Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opin Invest Drugs 11:755–768

    Article  CAS  Google Scholar 

  47. Salomon DS, Brandt R, Ciardiello F, Nornanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232

    Article  PubMed  CAS  Google Scholar 

  48. Nicodemus CF, Berek JS (2005) Monoclonal antibody therapy of ovarian cancer. Expert Rev Anticancer Ther 5:87–96

    Article  PubMed  CAS  Google Scholar 

  49. Ciardiello F, Bianco R, Damiano V et al (1999) Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Can Res 5:909–916

    CAS  Google Scholar 

  50. Aghajanian C, Sabbatini P, Derosa F et al (2005) Phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced stage ovarian, primary peritoneal and fallopian tube cancer. J Clin Oncol 23:5047

    Article  CAS  Google Scholar 

  51. Loibl R et al. Phase II study of gefitinib plus tamoxifen in patients refractory to platinum/taxane-based therapy (AGO Ovar 2.6)

  52. Finkler N, Gordon A, Crozier M et al (2001) Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma [abstract]. Proc Am Soc Clin Oncol 20:A831

    Google Scholar 

  53. Clark GM, Pérez-Soler R, Sin L et al (2003) Rash severity is predictive of increased survival with erlotinib HCl [abstract]. Proc Am Soc Clin Oncol 22:A786

    Google Scholar 

  54. Shen GH, Ghazizaden M, Kawanami O et al (2000) Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer 83:196–203

    Article  PubMed  CAS  Google Scholar 

  55. Zebrowski BK, Liu W, Ramirez K et al (1999) Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6:373–378

    Article  PubMed  CAS  Google Scholar 

  56. Presta L, Chen H, O’Connor SJ et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599

    PubMed  CAS  Google Scholar 

  57. Burger RA, Sill M, Monk BJ et al (2005) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study [abstract]. J Clin Oncol 23:A5009

    Google Scholar 

  58. Cannistra SA, Matulonis U, Penson R et al (2006) Bevacizumab in patients with advanced platinum-resistant ovarian cancer [abstract]. J Clin Oncol 24:A5006

    Google Scholar 

  59. Dupont J, Rothenberg ML, Spriggs DR et al (2005) Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. J Clin Oncol 23:A3029

    Google Scholar 

  60. Yao JC, Phan AT, Chang DZ et al (2006) Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET) [abstract]. J Clin Oncol 24:A4042

    Article  Google Scholar 

  61. Cascinu S, Del Ferro E, Ligi M et al (2001) Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 19:8–12

    Article  PubMed  CAS  Google Scholar 

  62. Pollak MN, Polychronakos C, Guyda H (1989) Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 9:889–891

    PubMed  CAS  Google Scholar 

  63. Sessa C, de Braud F, Perotti A et al (2005) Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867–1874

    Article  PubMed  CAS  Google Scholar 

  64. McMeekin DS, Krasner C, Chan S et al (2005) Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma. J Clin Oncol 23:A5011

    Google Scholar 

  65. Del Campo J, Roszak A, Ciuleanu T et al (2006) Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. J Clin Oncol 23:A5031

    Google Scholar 

  66. Poveda A (2005) Ovarian cancer: are the news good enough? Int J Gynecol Cancer 15[Suppl 3]:298–306

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Instituto Valenciano de Oncología, Beltrán Báguena, 4, ES-46009, Valencia, Spain

    A. Poveda

  2. Instituto Catalán de Oncología, Barcelona, Spain

    R. Salazar & A. Oaknin

  3. Division of Medical Oncology, Hospital Vall d’Hebrón, Barcelona, Spain

    J. M. del Campo

  4. Division of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain

    C. Mendiola

  5. Division of Medical Oncology, Hospital Universitario de Guadalajara, Guadalajara, Spain

    J. Cassinello

  6. Division of Medical Oncology, Hospital de Sant Pau, Barcelona, Spain

    B. Ojeda

  7. Division of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

    J. A. Arranz

  8. Division of Medical Oncology, Clínica Universitaria de Navarra, Pamplona, Spain

    J. García-Foncillas

  9. Division of Medical Oncology, Hospital Reina Sofía, Córdoba, Spain

    M. J. Rubio

  10. Hospital Universitario Ramón y Cajal, Madrid, Spain

    A. González Martín

Authors
  1. A. Poveda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Salazar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. M. del Campo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Mendiola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Cassinello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Ojeda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. A. Arranz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Oaknin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. García-Foncillas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. J. Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A. González Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Poveda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Poveda, A., Salazar, R., del Campo, J.M. et al. Update in the management of ovarian and cervical carcinoma. Clin Transl Oncol 9, 443–451 (2007). https://doi.org/10.1007/s12094-007-0083-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-007-0083-7

Key words

Search

Navigation